Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Allianz SE

Key Points

• Allianz SE increased its stake in Thermo Fisher Scientific by 5.1% during the first quarter, owning 15,822 shares valued at approximately $7.87 million.
• Analysts have varied price targets for Thermo Fisher Scientific, with objectives ranging from $470.00 to $670.00, while the stock currently holds a consensus rating of "Moderate Buy."
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, set to be paid on October 15th, reflecting a yield of 0.4% and a dividend payout ratio of 9.95%.

Allianz SE raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,822 shares of the medical research company's stock after purchasing an additional 762 shares during the period. Allianz SE's holdings in Thermo Fisher Scientific were worth $7,873,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $25,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $30,000. IMA Advisory Services Inc. acquired a new position in Thermo Fisher Scientific during the first quarter worth approximately $35,000. Navigoe LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the first quarter worth $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on TMO shares. Argus dropped their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Robert W. Baird increased their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. UBS Group increased their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Stifel Nicolaus dropped their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Finally, Raymond James Financial reissued an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 1.1%

NYSE TMO opened at $462.74 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market capitalization of $174.68 billion, a price-to-earnings ratio of 26.76, a price-to-earnings-growth ratio of 2.47 and a beta of 0.74. The company's fifty day moving average price is $420.88 and its two-hundred day moving average price is $467.07.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the firm posted $5.37 EPS. The firm's revenue was up 2.9% compared to the same quarter last year. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.